Evidence map›Paper›PMID 40935366›Full record

ArticleThoracic cancer2025

Clinical Significance of Time-to-Surgery and COVID-19 Pandemic in Surgically Treated Non-Small Cell Lung Cancer.

Áron Ghimessy, János Fillinger, Márton Csaba, Sára Lality, Gábor Tarsoly, Hanna Tihanyi, Kristóf Csende, Péter Radeczky, Balázs Gieszer, Levente Bogyó and 9 more

Abstract read
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Áron GhimessyDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.ORCID https://orcid.org/0000-0002-0385-1586
János FillingerNational Korányi Institute of Pulmonology, Budapest, Hungary.
Márton CsabaDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Sára LalityDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Gábor TarsolyDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Hanna TihanyiDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Kristóf CsendeDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Péter RadeczkyDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Balázs GieszerDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Levente BogyóDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Klára TörökDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
László MészárosDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Áron GellértDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Bence FerenczDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Balázs DömeDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.ORCID https://orcid.org/0000-0001-8799-8624
Ákos KocsisDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
László AgócsDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Ferenc Rényi-VámosDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.
Zsolt MegyesfalviDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary.

Funding

Austrian Science Fund FWF I3522Austrian Science Fund FWF I3977Austrian Science Fund I4677Bolyai Research Scholarship of the Hungarian Academy of SciencesHungarian National Research, Development and Innovation Office 2020-1.1.6-JÖVŐHungarian National Research, Development and Innovation Office KH130356Hungarian National Research, Development and Innovation Office KKP126790Hungarian National Research, Development and Innovation Office TKP2021-EGA-33New National Excellence Program of the Ministry for Innovation and Technology of Hungary UNKP-20-3New National Excellence Program of the Ministry for Innovation and Technology of Hungary UNKP-21-3New National Excellence Program of the Ministry for Innovation and Technology of Hungary UNKP-23-5Semmelweis University EFOP-3.6.3-VEKOP-16-2017-00009
6 · The paper itself

Abstract

objectivesTimely discovery and adequate patient management are crucial in non-small cell lung cancer (NSCLC) since long-term survival is only achievable in early-stage disease. In our study, we aimed to elucidate the effects of time to surgery on survival and to assess the impact of the COVID-19 pandemic on elapsed time until surgery.

methodsIn total, 2536 Caucasian NSCLC patients who underwent curative-intent lung resection surgery were included in this study. 1 month, 2 months, 77 days, and 91.06 days between CT-based diagnosis and surgery were evaluated as possible cut-off values for worse outcome. Survival curves were estimated by Kaplan-Meier plots, and the differences between groups were compared using the log-rank test. Multivariate analysis was performed using a Cox regression model.

resultsPatients with time-to-surgery ≥ 2 months had significantly impaired overall survival (OS) (vs. those with < 2 months; p = 0.002). In our multivariate model, time-to-surgery (p = 0.011), age (p = 0.02), diabetes mellitus (p = 0.02), disease stage (p = 0.0001) and vascular invasion (p < 0.001) all had a significant impact on OS. Importantly, during the COVID-19 pandemic, the elapsed time between diagnosis and surgery increased with a median of 12 days, resulting in a significant delay in time-to-surgery compared to the pre-pandemic period (p < 0.001). Post hoc tests showed, however, that there were no significant differences in time-to-surgery concerning the major waves of COVID-19 infections.

conclusionsTime-to-surgery is an independent predictor of long-term survival in surgically treated NSCLC. In general, the COVID-19 pandemic caused a significant delay in the elapsed time until surgery, but the specific COVID-19 waves had no significant impact on time-to-surgery.

Indexed as

Carcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsTime-to-TreatmentAgedAged, 80 and overClinical RelevanceFemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesSARS-CoV-2COVID‐19 pandemicNSCLCtime‐to‐surgery

Identifiers

PMID40935366
PMCPMC12425559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.